Looks like this new study is Prof. Claassen's product. This 15 cases are studied in Vanderbilt University Medical Center, where the bioMUSE study was done and now it is also one center for the main phase 2 study. So they very likely have MSA patients which did not meat inclusion criteria for bioMUSE study neither for the original phase 2 study, because they were too old for them. Claassen has been planing the phase 2 protocol with Stamler et al and they have all systems and devices to do this additional open-label biomarker study without a control group. In fact, biomarkers have demonstrated to be quite good in measuring disease activity.
Looks like this new study is Prof. Claassen's product. This 15...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $1.528K | 317.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97511267 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179254 | 15 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |